At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
CERE-120: Adeno-Associated Virus Delivery of Neurturin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating CERE-120: Adeno-Associated Virus Delivery of Neurturin and Sham Surgery for Idiopathic Parkinson's Disease. Completed, enrolled 57 participants across 11 sites.
Detailed Summary
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Parkinson's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionNov 2014
Study CompletionNov 2017
TodayJul 2026
First PostedSep 28, 2009
Enrollment StartOct 29, 2009
Primary CompletionNov 9, 2014
Study CompletionNov 16, 2017
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 16.8 years ago
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturinbiological
Sham Surgeryprocedure